09 Sep 2025 Avacta’s pre|CISION® Platform Shortlisted for the Technology of the Year Award at the AIM Awards Investors | Therapeutics
29 Aug 2025 Amendments to the Convertible Bond and equity fundraise of £3.25 million Investors | Therapeutics
30 Jul 2025 Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress Therapeutics
01 Jul 2025 Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development Investors | Therapeutics
28 Apr 2025 Research & Development Spotlight Series, Episode 9 Investors | R&D Spotlights Series | Therapeutics
28 Apr 2025 Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting Investors | Therapeutics
28 Apr 2025 Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting Investors | Therapeutics